Ben_the_King的个人主页 - 老虎社区

Ben_the_King

Ben_the_King

暂无个人介绍

IP属地：未知

65关注

8粉丝

0主题

0勋章

2022-01-25

$ZIM Integrated Shipping Services Ltd.(ZIM)$correction!

2022-01-24

$ZIM Integrated Shipping Services Ltd.(ZIM)$right decision? Hope so

2022-01-22

Good insight

@小虎综合资讯:图解财报 | 奈飞遭遇“滑铁卢”的四大原因

2022-01-20

$Star Bulk Carriers(SBLK)$correction yet come?

2021-12-17

$Futu Holdings Limited(FUTU)$seeing english media stated something incorrect, just to share chinese version. It clearly stating only ban Mainland Chinese citizen to trade A shares from HK.

2021-12-07

$Star Bulk Carriers(SBLK)$result of perseverance

2021-11-18

$Peloton Interactive, Inc.(PTON)$anyone know when will 1B new shares got listed?

2021-11-10

All electric cars at crazy valuation

EV maker Rivian prices IPO above range to raise over $11.9 billion

2021-11-08

$Star Bulk Carriers(SBLK)$finally you come.

2021-10-25

Really crazy valuation

Tesla soared over 4% and reached an all-time high at 970.84

2021-10-20

This NFT thing is really hard to comprehend, yet a billion dollar sector.

Coinbase Shares Jump On NBA Partnership: What Investors Should Know

2021-10-20

Becareful to enter, very risky if Novavax doesn't turn out to be as promising as the anticipation.

Novavax plunged over 20% in premarket trading

2021-10-05

$Futu Holdings Limited(FUTU)$second listing in HKSE!

2021-09-02

$Futu Holdings Limited(FUTU)$不错！

2021-08-31

$Futu Holdings Limited(FUTU)$券商爆发，今晚美股有好戏看了

2021-08-24

好就没那么爽了！

2021-07-08

$Tiger Brokers(TIGR)$吐血了

2021-06-25

$Missfresh Limited(MF)$中了25，好像比之前中得多，不是超额认购吗？

2021-06-24

$Missfresh Limited(MF)$尊敬的客户，接每日优鲜通知，因认购火爆，公司拟提前结束招股，预计6月25日正式上市。每日优鲜认购通道将于6月24日19:00（北京时间）关闭，如您意向认购或撤销，请在认购结束前操作，感谢您的理解和支持。如有问题请您联系客服400-603-7555。

2021-06-23

$Full Truck Alliance Co. Ltd.(YMM)$看到有报告说越迟开市就代表越多的订单要Match 才有办法订上市的价钱。所以越迟越好吧？

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3582161512309317,"uuid":"3582161512309317","gmtCreate":1619067489633,"gmtModify":1619422117299,"name":"Ben_the_King","pinyin":"benthekingbentheking","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":8,"headSize":65,"tweetSize":87,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.06.28","exceedPercentage":"93.85%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.42%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":639980436,"gmtCreate":1643120520742,"gmtModify":1643120520874,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZIM\">$ZIM Integrated Shipping Services Ltd.(ZIM)$</a>correction!","listText":"<a href=\"https://laohu8.com/S/ZIM\">$ZIM Integrated Shipping Services Ltd.(ZIM)$</a>correction!","text":"$ZIM Integrated Shipping Services Ltd.(ZIM)$correction!","images":[{"img":"https://static.tigerbbs.com/06d02ea906ad7803bfd7bc390f165069","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/639980436","isVote":1,"tweetType":1,"viewCount":801,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":630428453,"gmtCreate":1643026416922,"gmtModify":1643026417072,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZIM\">$ZIM Integrated Shipping Services Ltd.(ZIM)$</a>right decision? Hope so","listText":"<a href=\"https://laohu8.com/S/ZIM\">$ZIM Integrated Shipping Services Ltd.(ZIM)$</a>right decision? Hope so","text":"$ZIM Integrated Shipping Services Ltd.(ZIM)$right decision? Hope so","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630428453","isVote":1,"tweetType":1,"viewCount":724,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":630633740,"gmtCreate":1642808978890,"gmtModify":1642808979076,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good insight","listText":"Good insight","text":"Good insight","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630633740","repostId":"630808999","repostType":1,"repost":{"id":630808999,"gmtCreate":1642760372836,"gmtModify":1642760372836,"author":{"id":"3527667586584720","authorId":"3527667586584720","name":"小虎综合资讯","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"图解财报 | 奈飞遭遇“滑铁卢”的四大原因","htmlText":"周四，奈飞Q4财报公布后股价大跌，周五盘前继续跌势，不久前还因《鱿鱼游戏》火遍全球的科技巨头，为何坠入“至暗时刻”？","listText":"周四，奈飞Q4财报公布后股价大跌，周五盘前继续跌势，不久前还因《鱿鱼游戏》火遍全球的科技巨头，为何坠入“至暗时刻”？","text":"周四，奈飞Q4财报公布后股价大跌，周五盘前继续跌势，不久前还因《鱿鱼游戏》火遍全球的科技巨头，为何坠入“至暗时刻”？","images":[{"img":"https://static.tigerbbs.com/e43255443c4abf8889320585d25493d8","width":"750","height":"6580"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630808999","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":600,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":630924613,"gmtCreate":1642672953448,"gmtModify":1642672953585,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SBLK\">$Star Bulk Carriers(SBLK)$</a>correction yet come?&nbsp;","listText":"<a href=\"https://laohu8.com/S/SBLK\">$Star Bulk Carriers(SBLK)$</a>correction yet come?&nbsp;","text":"$Star Bulk Carriers(SBLK)$correction yet come?","images":[{"img":"https://static.tigerbbs.com/6305ca6e7aa7fc2d5b46d3f9f79cde21","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630924613","isVote":1,"tweetType":1,"viewCount":747,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":699139726,"gmtCreate":1639754344501,"gmtModify":1639754397052,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>seeing english media stated something incorrect, just to share chinese version. It clearly stating only ban Mainland Chinese citizen to trade A shares from HK.","listText":"<a href=\"https://laohu8.com/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>seeing english media stated something incorrect, just to share chinese version. It clearly stating only ban Mainland Chinese citizen to trade A shares from HK.","text":"$Futu Holdings Limited(FUTU)$seeing english media stated something incorrect, just to share chinese version. It clearly stating only ban Mainland Chinese citizen to trade A shares from HK.","images":[{"img":"https://static.tigerbbs.com/380e87351e461288e468f01865b9f494","width":"1080","height":"2340"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699139726","isVote":1,"tweetType":1,"viewCount":1337,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":606245554,"gmtCreate":1638888758239,"gmtModify":1638888758358,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SBLK\">$Star Bulk Carriers(SBLK)$</a>result of perseverance","listText":"<a href=\"https://laohu8.com/S/SBLK\">$Star Bulk Carriers(SBLK)$</a>result of perseverance","text":"$Star Bulk Carriers(SBLK)$result of perseverance","images":[{"img":"https://static.tigerbbs.com/883742c732dfc220779ac42190545e1d","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606245554","isVote":1,"tweetType":1,"viewCount":591,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":876911760,"gmtCreate":1637248607393,"gmtModify":1637248607503,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PTON\">$Peloton Interactive, Inc.(PTON)$</a>anyone know when will 1B new shares got listed?","listText":"<a href=\"https://laohu8.com/S/PTON\">$Peloton Interactive, Inc.(PTON)$</a>anyone know when will 1B new shares got listed?","text":"$Peloton Interactive, Inc.(PTON)$anyone know when will 1B new shares got listed?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/876911760","isVote":1,"tweetType":1,"viewCount":716,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847456838,"gmtCreate":1636548911950,"gmtModify":1636548912173,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"All electric cars at crazy valuation","listText":"All electric cars at crazy valuation","text":"All electric cars at crazy valuation","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847456838","repostId":"1127288999","repostType":2,"repost":{"id":"1127288999","pubTimestamp":1636525634,"share":"https://www.laohu8.com/m/news/1127288999?lang=&edition=full","pubTime":"2021-11-10 14:27","market":"us","language":"en","title":"EV maker Rivian prices IPO above range to raise over $11.9 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1127288999","media":"Reuters","summary":"NEW YORK (Reuters) - Amazon-backed electric vehicle (EV) maker Rivian sold shares in its initial pub","content":"<p>NEW YORK (Reuters) - Amazon-backed electric vehicle (EV) maker Rivian sold shares in its initial public offering (IPO) at $78 per share, above its target range, to raise more than $11.93 billion, the company said on Tuesday.</p>\n<p>The flotation ranks among the top 10 IPOs of all time in the United States, according to data from Dealogic.</p>\n<p>Rivian priced an upsized IPO of 153 million shares at $78 per share, the company&nbsp;said. On Friday, Rivian had boosted its price range to $72 to $74 per share, up from an earlier range of $57 to $62.</p>\n<p>The mammoth IPO follows a highly successful investor roadshow last week, with Wall Street's biggest institutional investors betting on Rivian to be the next big player in a sector dominated by Tesla.</p>\n<p>The EV market is witnessing a surge in demand globally, as consumers are growing more environmentally conscious and betting on eco-friendly vehicles. Tesla produced a record number of cars in its latest quarter and is building factories all over the world.</p>\n<p>Founded in 2009, Rivian has been investing heavily to ramp up production. It is doubling down on production of its upscale all-electric R1T pickup truck, which was launched in September.</p>\n<p>The EV maker had about 55,400 R1T and R1S pre-orders in the United States and Canada as of Oct. 31, according to a recent regulatory filing.</p>\n<p>Rivian said it had started deliveries of the R1T and had recorded revenue for the three months ended Sept. 30. The net loss for that period, however, is estimated to increase due to higher production costs.</p>\n<p>Amazon, which recently disclosed it holds an approximately 20% stake in Rivian, has ordered 100,000 of Rivian's electric delivery vans as part of the e-commerce company's broader effort to cut its carbon footprint.</p>\n<p>Rivian will list its shares on the Nasdaq under the symbol \"RIVN\" on Wednesday.</p>\n<p>Morgan Stanley, Goldman Sachs and J.P. Morgan are the lead underwriters for the offering.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV maker Rivian prices IPO above range to raise over $11.9 billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV maker Rivian prices IPO above range to raise over $11.9 billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-10 14:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ev-maker-rivian-prices-ipo-002047558.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (Reuters) - Amazon-backed electric vehicle (EV) maker Rivian sold shares in its initial public offering (IPO) at $78 per share, above its target range, to raise more than $11.93 billion, the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ev-maker-rivian-prices-ipo-002047558.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc."},"source_url":"https://finance.yahoo.com/news/ev-maker-rivian-prices-ipo-002047558.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127288999","content_text":"NEW YORK (Reuters) - Amazon-backed electric vehicle (EV) maker Rivian sold shares in its initial public offering (IPO) at $78 per share, above its target range, to raise more than $11.93 billion, the company said on Tuesday.\nThe flotation ranks among the top 10 IPOs of all time in the United States, according to data from Dealogic.\nRivian priced an upsized IPO of 153 million shares at $78 per share, the company said. On Friday, Rivian had boosted its price range to $72 to $74 per share, up from an earlier range of $57 to $62.\nThe mammoth IPO follows a highly successful investor roadshow last week, with Wall Street's biggest institutional investors betting on Rivian to be the next big player in a sector dominated by Tesla.\nThe EV market is witnessing a surge in demand globally, as consumers are growing more environmentally conscious and betting on eco-friendly vehicles. Tesla produced a record number of cars in its latest quarter and is building factories all over the world.\nFounded in 2009, Rivian has been investing heavily to ramp up production. It is doubling down on production of its upscale all-electric R1T pickup truck, which was launched in September.\nThe EV maker had about 55,400 R1T and R1S pre-orders in the United States and Canada as of Oct. 31, according to a recent regulatory filing.\nRivian said it had started deliveries of the R1T and had recorded revenue for the three months ended Sept. 30. The net loss for that period, however, is estimated to increase due to higher production costs.\nAmazon, which recently disclosed it holds an approximately 20% stake in Rivian, has ordered 100,000 of Rivian's electric delivery vans as part of the e-commerce company's broader effort to cut its carbon footprint.\nRivian will list its shares on the Nasdaq under the symbol \"RIVN\" on Wednesday.\nMorgan Stanley, Goldman Sachs and J.P. Morgan are the lead underwriters for the offering.","news_type":1},"isVote":1,"tweetType":1,"viewCount":745,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844037068,"gmtCreate":1636376385646,"gmtModify":1636376385822,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SBLK\">$Star Bulk Carriers(SBLK)$</a>finally you come.","listText":"<a href=\"https://laohu8.com/S/SBLK\">$Star Bulk Carriers(SBLK)$</a>finally you come.","text":"$Star Bulk Carriers(SBLK)$finally you come.","images":[{"img":"https://static.tigerbbs.com/ef4e1719cb74e805eb51a08a609a0d0a","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/844037068","isVote":1,"tweetType":1,"viewCount":759,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":856845325,"gmtCreate":1635170605529,"gmtModify":1635170630800,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Really crazy valuation","listText":"Really crazy valuation","text":"Really crazy valuation","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/856845325","repostId":"1182032279","repostType":2,"repost":{"id":"1182032279","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635169235,"share":"https://www.laohu8.com/m/news/1182032279?lang=&edition=full","pubTime":"2021-10-25 21:40","market":"us","language":"en","title":"Tesla soared over 4% and reached an all-time high at 970.84","url":"https://stock-news.laohu8.com/highlight/detail?id=1182032279","media":"Tiger Newspress","summary":"Tesla soared over 4% and reached an all-time high at 970.84.Tesla Inc has increased the price of its","content":"<p>Tesla soared over 4% and reached an all-time high at 970.84.<img src=\"https://static.tigerbbs.com/304a2b85f054f5b849d1ef1d8c85c7c7\" tg-width=\"766\" tg-height=\"565\" width=\"100%\" height=\"auto\">Tesla Inc has increased the price of its Model X Long Range and Model S Long Range variants by $5,000, the electric-car maker's website showed on Saturday.</p>\n<p>The Model X Long Range and Model S Long Range now sell for $104,990 and $94,990 respectively.</p>\n<p>Prices for the Model Y Long Range and Model 3 Standard Range Plus rose by $2,000, to $56,990 and $43,990 respectively, according to the website.</p>\n<p>Moreover,Hertz Global Holdings Inc., barely four months out of bankruptcy, placed an order for 100,000 Teslas in the first step of an ambitious plan to electrify its rental-car fleet, according to people with knowledge of the matter, Bloomberg News reports.</p>\n<p>It’s the single-largest purchase ever for electric vehicles and represents about $4.2 billion of revenue forTesla Inc., according to the people, who asked not to be identified because the information is private.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla soared over 4% and reached an all-time high at 970.84</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla soared over 4% and reached an all-time high at 970.84\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-25 21:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tesla soared over 4% and reached an all-time high at 970.84.<img src=\"https://static.tigerbbs.com/304a2b85f054f5b849d1ef1d8c85c7c7\" tg-width=\"766\" tg-height=\"565\" width=\"100%\" height=\"auto\">Tesla Inc has increased the price of its Model X Long Range and Model S Long Range variants by $5,000, the electric-car maker's website showed on Saturday.</p>\n<p>The Model X Long Range and Model S Long Range now sell for $104,990 and $94,990 respectively.</p>\n<p>Prices for the Model Y Long Range and Model 3 Standard Range Plus rose by $2,000, to $56,990 and $43,990 respectively, according to the website.</p>\n<p>Moreover,Hertz Global Holdings Inc., barely four months out of bankruptcy, placed an order for 100,000 Teslas in the first step of an ambitious plan to electrify its rental-car fleet, according to people with knowledge of the matter, Bloomberg News reports.</p>\n<p>It’s the single-largest purchase ever for electric vehicles and represents about $4.2 billion of revenue forTesla Inc., according to the people, who asked not to be identified because the information is private.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182032279","content_text":"Tesla soared over 4% and reached an all-time high at 970.84.Tesla Inc has increased the price of its Model X Long Range and Model S Long Range variants by $5,000, the electric-car maker's website showed on Saturday.\nThe Model X Long Range and Model S Long Range now sell for $104,990 and $94,990 respectively.\nPrices for the Model Y Long Range and Model 3 Standard Range Plus rose by $2,000, to $56,990 and $43,990 respectively, according to the website.\nMoreover,Hertz Global Holdings Inc., barely four months out of bankruptcy, placed an order for 100,000 Teslas in the first step of an ambitious plan to electrify its rental-car fleet, according to people with knowledge of the matter, Bloomberg News reports.\nIt’s the single-largest purchase ever for electric vehicles and represents about $4.2 billion of revenue forTesla Inc., according to the people, who asked not to be identified because the information is private.","news_type":1},"isVote":1,"tweetType":1,"viewCount":841,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859791663,"gmtCreate":1634731438214,"gmtModify":1634731492085,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"This NFT thing is really hard to comprehend, yet a billion dollar sector.","listText":"This NFT thing is really hard to comprehend, yet a billion dollar sector.","text":"This NFT thing is really hard to comprehend, yet a billion dollar sector.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859791663","repostId":"1157555199","repostType":2,"repost":{"id":"1157555199","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1634693372,"share":"https://www.laohu8.com/m/news/1157555199?lang=&edition=full","pubTime":"2021-10-20 09:29","market":"us","language":"en","title":"Coinbase Shares Jump On NBA Partnership: What Investors Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=1157555199","media":"Benzinga","summary":"A leading cryptocurrency platform announced a partnership with the National Basketball Association o","content":"<p>A leading cryptocurrency platform announced a partnership with the National Basketball Association on the day the league is set to kick off its 75th anniversary.</p>\n<p><img src=\"https://static.tigerbbs.com/71c079c80776647184cfcb0bff977ce5\" tg-width=\"720\" tg-height=\"378\" width=\"100%\" height=\"auto\"></p>\n<p><b>What Happened:</b>The National Basketball Association announced its first cryptocurrency sponsorship in a partnerhsip with&nbsp;<b>Coinbase Global Inc.</b></p>\n<p>“We’re excited to announce that as of today we are the official crypto platform of the NBA, WNBA, NBA2KLeague and USA Basketball,” Coinbasetweeted,&nbsp;tagging the respective leagues.</p>\n<p>“As part of the partnership, we will create interactive experiences to engage with the NBA and WNBA’s incredible community and athletes around the world,\" Coinbase Chief Marketing Officer&nbsp;<b>Kate Rouch</b>&nbsp;told&nbsp;CNBC&nbsp;in a statement.</p>\n<p><b>Why It’s Important:</b>The NBA&nbsp;has been earlier with&nbsp;cryptocurrency and&nbsp;NFTs. The league has&nbsp;the highly&nbsp;successful&nbsp;NBA Top Shot partnership with&nbsp;<b>Dapper Labs</b>. The Miami Heat have an arena naming deal with&nbsp;<b>FTX</b>&nbsp;and several teams have patch sponsorships with cryptocurrency companies.</p>\n<p>The NBA is projecting $10 billion in revenue for the 2021-22 season thanks to the return of fans. Sponsorship revenue was $1.4 billion last season.</p>\n<p>The NBA kicks off its 75th season with a doubleheader of marquee matchups. The Brooklyn Nets take on the Milwaukee Bucks at 7:30 p.m. ET and the Golden State Warriors take on the Los Angeles Lakers at 10 p.m. ET. Both games will air on TNT, a unit of&nbsp;<b>AT&amp;T Inc.</b></p>\n<p><b>COIN Price Action:</b>Coinbase&nbsp;shares were up 4% to $305.63 on Tuesday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coinbase Shares Jump On NBA Partnership: What Investors Should Know</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoinbase Shares Jump On NBA Partnership: What Investors Should Know\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-10-20 09:29</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>A leading cryptocurrency platform announced a partnership with the National Basketball Association on the day the league is set to kick off its 75th anniversary.</p>\n<p><img src=\"https://static.tigerbbs.com/71c079c80776647184cfcb0bff977ce5\" tg-width=\"720\" tg-height=\"378\" width=\"100%\" height=\"auto\"></p>\n<p><b>What Happened:</b>The National Basketball Association announced its first cryptocurrency sponsorship in a partnerhsip with&nbsp;<b>Coinbase Global Inc.</b></p>\n<p>“We’re excited to announce that as of today we are the official crypto platform of the NBA, WNBA, NBA2KLeague and USA Basketball,” Coinbasetweeted,&nbsp;tagging the respective leagues.</p>\n<p>“As part of the partnership, we will create interactive experiences to engage with the NBA and WNBA’s incredible community and athletes around the world,\" Coinbase Chief Marketing Officer&nbsp;<b>Kate Rouch</b>&nbsp;told&nbsp;CNBC&nbsp;in a statement.</p>\n<p><b>Why It’s Important:</b>The NBA&nbsp;has been earlier with&nbsp;cryptocurrency and&nbsp;NFTs. The league has&nbsp;the highly&nbsp;successful&nbsp;NBA Top Shot partnership with&nbsp;<b>Dapper Labs</b>. The Miami Heat have an arena naming deal with&nbsp;<b>FTX</b>&nbsp;and several teams have patch sponsorships with cryptocurrency companies.</p>\n<p>The NBA is projecting $10 billion in revenue for the 2021-22 season thanks to the return of fans. Sponsorship revenue was $1.4 billion last season.</p>\n<p>The NBA kicks off its 75th season with a doubleheader of marquee matchups. The Brooklyn Nets take on the Milwaukee Bucks at 7:30 p.m. ET and the Golden State Warriors take on the Los Angeles Lakers at 10 p.m. ET. Both games will air on TNT, a unit of&nbsp;<b>AT&amp;T Inc.</b></p>\n<p><b>COIN Price Action:</b>Coinbase&nbsp;shares were up 4% to $305.63 on Tuesday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157555199","content_text":"A leading cryptocurrency platform announced a partnership with the National Basketball Association on the day the league is set to kick off its 75th anniversary.\n\nWhat Happened:The National Basketball Association announced its first cryptocurrency sponsorship in a partnerhsip with Coinbase Global Inc.\n“We’re excited to announce that as of today we are the official crypto platform of the NBA, WNBA, NBA2KLeague and USA Basketball,” Coinbasetweeted, tagging the respective leagues.\n“As part of the partnership, we will create interactive experiences to engage with the NBA and WNBA’s incredible community and athletes around the world,\" Coinbase Chief Marketing Officer Kate Rouch told CNBC in a statement.\nWhy It’s Important:The NBA has been earlier with cryptocurrency and NFTs. The league has the highly successful NBA Top Shot partnership with Dapper Labs. The Miami Heat have an arena naming deal with FTX and several teams have patch sponsorships with cryptocurrency companies.\nThe NBA is projecting $10 billion in revenue for the 2021-22 season thanks to the return of fans. Sponsorship revenue was $1.4 billion last season.\nThe NBA kicks off its 75th season with a doubleheader of marquee matchups. The Brooklyn Nets take on the Milwaukee Bucks at 7:30 p.m. ET and the Golden State Warriors take on the Los Angeles Lakers at 10 p.m. ET. Both games will air on TNT, a unit of AT&T Inc.\nCOIN Price Action:Coinbase shares were up 4% to $305.63 on Tuesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859461817,"gmtCreate":1634722390992,"gmtModify":1634722391152,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Becareful to enter, very risky if Novavax doesn't turn out to be as promising as the anticipation.&nbsp;","listText":"Becareful to enter, very risky if Novavax doesn't turn out to be as promising as the anticipation.&nbsp;","text":"Becareful to enter, very risky if Novavax doesn't turn out to be as promising as the anticipation.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/859461817","repostId":"1174375951","repostType":2,"repost":{"id":"1174375951","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634717661,"share":"https://www.laohu8.com/m/news/1174375951?lang=&edition=full","pubTime":"2021-10-20 16:14","market":"us","language":"en","title":"Novavax plunged over 20% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1174375951","media":"Tiger Newspress","summary":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the pr","content":"<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p>\n<p><img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p>\n<p>But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p>\n<p>The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p>\n<p>The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p>\n<p>Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p>\n<p>The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p>\n<p>COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p>\n<p>“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p>\n<p>The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p>\n<p>Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p>\n<p>In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p>\n<p>“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p>\n<p>The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p>\n<p>But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p>\n<p>Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p>\n<p>Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p>\n<p>The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p>\n<p>That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p>\n<p>Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p>\n<p>J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p>\n<p>“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p>\n<p>Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p>\n<p>Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p>\n<p>The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p>\n<p>But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p>\n<p>In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p>\n<p>“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p>\n<p>Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p>\n<p>Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p>\n<p>“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p>\n<p>U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p>\n<p>And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p>\n<p>Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p>\n<p>“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax plunged over 20% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax plunged over 20% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-20 16:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p>\n<p><img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p>\n<p>But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p>\n<p>The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p>\n<p>The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p>\n<p>Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p>\n<p>The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p>\n<p>COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p>\n<p>“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p>\n<p>The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p>\n<p>Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p>\n<p>In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p>\n<p>“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p>\n<p>The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p>\n<p>But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p>\n<p>Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p>\n<p>Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p>\n<p>The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p>\n<p>That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p>\n<p>Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p>\n<p>J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p>\n<p>“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p>\n<p>Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p>\n<p>Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p>\n<p>The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p>\n<p>But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p>\n<p>In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p>\n<p>“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p>\n<p>Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p>\n<p>Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p>\n<p>“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p>\n<p>U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p>\n<p>And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p>\n<p>Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p>\n<p>“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174375951","content_text":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.\nThe world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.\nBut the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.\nThe delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.\nThe U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.\nAlthough Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.\nThe Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, one of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.\nCOVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.\n“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the Duke Global Health Innovation Center.\nThe global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.\nBetween Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.\nIn a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.\n“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.\nThe White House and the Department of Health and Human Services did not respond to multiple requests for comment.\nBut three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.\nNovavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.\nUnlike Pfizer and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.\nThe revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.\nThat includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.\nNovavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson & Johnsonhalted work at a Baltimore facilityrun by contract manufacturer Emergent BioSolutions after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.\nJ&J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.\n“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”\nUnlike Johnson & Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.\nYet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.\nThe contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.\nBut even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.\nIn particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.\n“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”\nTaylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.\nCompany executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.\n“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”\nU.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&J’s vaccine at the Emergent plant earlier this year, those people said.\nAnd even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.\nSeveral vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.\n“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":563,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":820706601,"gmtCreate":1633427138725,"gmtModify":1633427138933,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>second listing in HKSE!&nbsp;","listText":"<a href=\"https://laohu8.com/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>second listing in HKSE!&nbsp;","text":"$Futu Holdings Limited(FUTU)$second listing in HKSE!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820706601","isVote":1,"tweetType":1,"viewCount":110,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":812243156,"gmtCreate":1630591990275,"gmtModify":1631883690453,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>不错！","listText":"<a href=\"https://laohu8.com/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>不错！","text":"$Futu Holdings Limited(FUTU)$不错！","images":[{"img":"https://static.tigerbbs.com/37cdefb792cf5984324f3703066cfc1a","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812243156","isVote":1,"tweetType":1,"viewCount":359,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":818845624,"gmtCreate":1630398796768,"gmtModify":1631883690789,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>券商爆发，今晚美股有好戏看了","listText":"<a href=\"https://laohu8.com/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>券商爆发，今晚美股有好戏看了","text":"$Futu Holdings Limited(FUTU)$券商爆发，今晚美股有好戏看了","images":[{"img":"https://static.tigerbbs.com/4639169bb8acead2c8c809204114e57b","width":"1080","height":"2340"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/818845624","isVote":1,"tweetType":1,"viewCount":502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":834490871,"gmtCreate":1629816941793,"gmtModify":1633682222099,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"好就没那么爽了！","listText":"好就没那么爽了！","text":"好就没那么爽了！","images":[{"img":"https://static.tigerbbs.com/34cf48712102c1579cb70b53d0113177","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/834490871","isVote":1,"tweetType":1,"viewCount":70,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":149208538,"gmtCreate":1625727041724,"gmtModify":1633937955301,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>吐血了","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>吐血了","text":"$Tiger Brokers(TIGR)$吐血了","images":[{"img":"https://static.tigerbbs.com/b3dfffcabec7bcfa52cddf5913330509","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/149208538","isVote":1,"tweetType":1,"viewCount":151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":122451211,"gmtCreate":1624630962233,"gmtModify":1633950291065,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MF\">$Missfresh Limited(MF)$</a>中了25，好像比之前中得多，不是超额认购吗？","listText":"<a href=\"https://laohu8.com/S/MF\">$Missfresh Limited(MF)$</a>中了25，好像比之前中得多，不是超额认购吗？","text":"$Missfresh Limited(MF)$中了25，好像比之前中得多，不是超额认购吗？","images":[{"img":"https://static.tigerbbs.com/2fb94d777c38bb4ecf1ac63bf33d8afa","width":"1087","height":"1935"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/122451211","isVote":1,"tweetType":1,"viewCount":1352,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":128496090,"gmtCreate":1624526472310,"gmtModify":1634004866125,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MF\">$Missfresh Limited(MF)$</a>尊敬的客户，接每日优鲜通知，因认购火爆，公司拟提前结束招股，预计6月25日正式上市。每日优鲜认购通道将于6月24日19:00（北京时间）关闭，如您意向认购或撤销，请在认购结束前操作，感谢您的理解和支持。如有问题请您联系客服400-603-7555。","listText":"<a href=\"https://laohu8.com/S/MF\">$Missfresh Limited(MF)$</a>尊敬的客户，接每日优鲜通知，因认购火爆，公司拟提前结束招股，预计6月25日正式上市。每日优鲜认购通道将于6月24日19:00（北京时间）关闭，如您意向认购或撤销，请在认购结束前操作，感谢您的理解和支持。如有问题请您联系客服400-603-7555。","text":"$Missfresh Limited(MF)$尊敬的客户，接每日优鲜通知，因认购火爆，公司拟提前结束招股，预计6月25日正式上市。每日优鲜认购通道将于6月24日19:00（北京时间）关闭，如您意向认购或撤销，请在认购结束前操作，感谢您的理解和支持。如有问题请您联系客服400-603-7555。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128496090","isVote":1,"tweetType":1,"viewCount":284,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":129495738,"gmtCreate":1624379967324,"gmtModify":1634006945402,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/YMM\">$Full Truck Alliance Co. Ltd.(YMM)$</a>看到有报告说越迟开市就代表越多的订单要Match 才有办法订上市的价钱。所以越迟越好吧？&nbsp;","listText":"<a href=\"https://laohu8.com/S/YMM\">$Full Truck Alliance Co. Ltd.(YMM)$</a>看到有报告说越迟开市就代表越多的订单要Match 才有办法订上市的价钱。所以越迟越好吧？&nbsp;","text":"$Full Truck Alliance Co. Ltd.(YMM)$看到有报告说越迟开市就代表越多的订单要Match 才有办法订上市的价钱。所以越迟越好吧？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":1,"link":"https://laohu8.com/post/129495738","isVote":1,"tweetType":1,"viewCount":3890,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":129495738,"gmtCreate":1624379967324,"gmtModify":1634006945402,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/YMM\">$Full Truck Alliance Co. Ltd.(YMM)$</a>看到有报告说越迟开市就代表越多的订单要Match 才有办法订上市的价钱。所以越迟越好吧？&nbsp;","listText":"<a href=\"https://laohu8.com/S/YMM\">$Full Truck Alliance Co. Ltd.(YMM)$</a>看到有报告说越迟开市就代表越多的订单要Match 才有办法订上市的价钱。所以越迟越好吧？&nbsp;","text":"$Full Truck Alliance Co. Ltd.(YMM)$看到有报告说越迟开市就代表越多的订单要Match 才有办法订上市的价钱。所以越迟越好吧？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":1,"link":"https://laohu8.com/post/129495738","isVote":1,"tweetType":1,"viewCount":3890,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859461817,"gmtCreate":1634722390992,"gmtModify":1634722391152,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Becareful to enter, very risky if Novavax doesn't turn out to be as promising as the anticipation.&nbsp;","listText":"Becareful to enter, very risky if Novavax doesn't turn out to be as promising as the anticipation.&nbsp;","text":"Becareful to enter, very risky if Novavax doesn't turn out to be as promising as the anticipation.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/859461817","repostId":"1174375951","repostType":2,"repost":{"id":"1174375951","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634717661,"share":"https://www.laohu8.com/m/news/1174375951?lang=&edition=full","pubTime":"2021-10-20 16:14","market":"us","language":"en","title":"Novavax plunged over 20% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1174375951","media":"Tiger Newspress","summary":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the pr","content":"<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p>\n<p><img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p>\n<p>But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p>\n<p>The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p>\n<p>The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p>\n<p>Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p>\n<p>The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p>\n<p>COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p>\n<p>“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p>\n<p>The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p>\n<p>Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p>\n<p>In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p>\n<p>“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p>\n<p>The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p>\n<p>But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p>\n<p>Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p>\n<p>Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p>\n<p>The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p>\n<p>That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p>\n<p>Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p>\n<p>J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p>\n<p>“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p>\n<p>Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p>\n<p>Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p>\n<p>The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p>\n<p>But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p>\n<p>In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p>\n<p>“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p>\n<p>Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p>\n<p>Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p>\n<p>“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p>\n<p>U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p>\n<p>And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p>\n<p>Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p>\n<p>“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax plunged over 20% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax plunged over 20% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-20 16:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p>\n<p><img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p>\n<p>But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p>\n<p>The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p>\n<p>The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p>\n<p>Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p>\n<p>The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p>\n<p>COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p>\n<p>“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p>\n<p>The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p>\n<p>Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p>\n<p>In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p>\n<p>“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p>\n<p>The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p>\n<p>But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p>\n<p>Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p>\n<p>Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p>\n<p>The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p>\n<p>That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p>\n<p>Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p>\n<p>J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p>\n<p>“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p>\n<p>Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p>\n<p>Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p>\n<p>The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p>\n<p>But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p>\n<p>In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p>\n<p>“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p>\n<p>Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p>\n<p>Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p>\n<p>“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p>\n<p>U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p>\n<p>And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p>\n<p>Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p>\n<p>“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174375951","content_text":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.\nThe world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.\nBut the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.\nThe delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.\nThe U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.\nAlthough Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.\nThe Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, one of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.\nCOVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.\n“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the Duke Global Health Innovation Center.\nThe global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.\nBetween Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.\nIn a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.\n“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.\nThe White House and the Department of Health and Human Services did not respond to multiple requests for comment.\nBut three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.\nNovavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.\nUnlike Pfizer and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.\nThe revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.\nThat includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.\nNovavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson & Johnsonhalted work at a Baltimore facilityrun by contract manufacturer Emergent BioSolutions after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.\nJ&J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.\n“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”\nUnlike Johnson & Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.\nYet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.\nThe contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.\nBut even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.\nIn particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.\n“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”\nTaylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.\nCompany executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.\n“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”\nU.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&J’s vaccine at the Emergent plant earlier this year, those people said.\nAnd even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.\nSeveral vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.\n“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":563,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856845325,"gmtCreate":1635170605529,"gmtModify":1635170630800,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Really crazy valuation","listText":"Really crazy valuation","text":"Really crazy valuation","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/856845325","repostId":"1182032279","repostType":2,"repost":{"id":"1182032279","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635169235,"share":"https://www.laohu8.com/m/news/1182032279?lang=&edition=full","pubTime":"2021-10-25 21:40","market":"us","language":"en","title":"Tesla soared over 4% and reached an all-time high at 970.84","url":"https://stock-news.laohu8.com/highlight/detail?id=1182032279","media":"Tiger Newspress","summary":"Tesla soared over 4% and reached an all-time high at 970.84.Tesla Inc has increased the price of its","content":"<p>Tesla soared over 4% and reached an all-time high at 970.84.<img src=\"https://static.tigerbbs.com/304a2b85f054f5b849d1ef1d8c85c7c7\" tg-width=\"766\" tg-height=\"565\" width=\"100%\" height=\"auto\">Tesla Inc has increased the price of its Model X Long Range and Model S Long Range variants by $5,000, the electric-car maker's website showed on Saturday.</p>\n<p>The Model X Long Range and Model S Long Range now sell for $104,990 and $94,990 respectively.</p>\n<p>Prices for the Model Y Long Range and Model 3 Standard Range Plus rose by $2,000, to $56,990 and $43,990 respectively, according to the website.</p>\n<p>Moreover,Hertz Global Holdings Inc., barely four months out of bankruptcy, placed an order for 100,000 Teslas in the first step of an ambitious plan to electrify its rental-car fleet, according to people with knowledge of the matter, Bloomberg News reports.</p>\n<p>It’s the single-largest purchase ever for electric vehicles and represents about $4.2 billion of revenue forTesla Inc., according to the people, who asked not to be identified because the information is private.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla soared over 4% and reached an all-time high at 970.84</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla soared over 4% and reached an all-time high at 970.84\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-25 21:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tesla soared over 4% and reached an all-time high at 970.84.<img src=\"https://static.tigerbbs.com/304a2b85f054f5b849d1ef1d8c85c7c7\" tg-width=\"766\" tg-height=\"565\" width=\"100%\" height=\"auto\">Tesla Inc has increased the price of its Model X Long Range and Model S Long Range variants by $5,000, the electric-car maker's website showed on Saturday.</p>\n<p>The Model X Long Range and Model S Long Range now sell for $104,990 and $94,990 respectively.</p>\n<p>Prices for the Model Y Long Range and Model 3 Standard Range Plus rose by $2,000, to $56,990 and $43,990 respectively, according to the website.</p>\n<p>Moreover,Hertz Global Holdings Inc., barely four months out of bankruptcy, placed an order for 100,000 Teslas in the first step of an ambitious plan to electrify its rental-car fleet, according to people with knowledge of the matter, Bloomberg News reports.</p>\n<p>It’s the single-largest purchase ever for electric vehicles and represents about $4.2 billion of revenue forTesla Inc., according to the people, who asked not to be identified because the information is private.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182032279","content_text":"Tesla soared over 4% and reached an all-time high at 970.84.Tesla Inc has increased the price of its Model X Long Range and Model S Long Range variants by $5,000, the electric-car maker's website showed on Saturday.\nThe Model X Long Range and Model S Long Range now sell for $104,990 and $94,990 respectively.\nPrices for the Model Y Long Range and Model 3 Standard Range Plus rose by $2,000, to $56,990 and $43,990 respectively, according to the website.\nMoreover,Hertz Global Holdings Inc., barely four months out of bankruptcy, placed an order for 100,000 Teslas in the first step of an ambitious plan to electrify its rental-car fleet, according to people with knowledge of the matter, Bloomberg News reports.\nIt’s the single-largest purchase ever for electric vehicles and represents about $4.2 billion of revenue forTesla Inc., according to the people, who asked not to be identified because the information is private.","news_type":1},"isVote":1,"tweetType":1,"viewCount":841,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876911760,"gmtCreate":1637248607393,"gmtModify":1637248607503,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PTON\">$Peloton Interactive, Inc.(PTON)$</a>anyone know when will 1B new shares got listed?","listText":"<a href=\"https://laohu8.com/S/PTON\">$Peloton Interactive, Inc.(PTON)$</a>anyone know when will 1B new shares got listed?","text":"$Peloton Interactive, Inc.(PTON)$anyone know when will 1B new shares got listed?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/876911760","isVote":1,"tweetType":1,"viewCount":716,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844037068,"gmtCreate":1636376385646,"gmtModify":1636376385822,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SBLK\">$Star Bulk Carriers(SBLK)$</a>finally you come.","listText":"<a href=\"https://laohu8.com/S/SBLK\">$Star Bulk Carriers(SBLK)$</a>finally you come.","text":"$Star Bulk Carriers(SBLK)$finally you come.","images":[{"img":"https://static.tigerbbs.com/ef4e1719cb74e805eb51a08a609a0d0a","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/844037068","isVote":1,"tweetType":1,"viewCount":759,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":122451211,"gmtCreate":1624630962233,"gmtModify":1633950291065,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MF\">$Missfresh Limited(MF)$</a>中了25，好像比之前中得多，不是超额认购吗？","listText":"<a href=\"https://laohu8.com/S/MF\">$Missfresh Limited(MF)$</a>中了25，好像比之前中得多，不是超额认购吗？","text":"$Missfresh Limited(MF)$中了25，好像比之前中得多，不是超额认购吗？","images":[{"img":"https://static.tigerbbs.com/2fb94d777c38bb4ecf1ac63bf33d8afa","width":"1087","height":"1935"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/122451211","isVote":1,"tweetType":1,"viewCount":1352,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":699139726,"gmtCreate":1639754344501,"gmtModify":1639754397052,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>seeing english media stated something incorrect, just to share chinese version. It clearly stating only ban Mainland Chinese citizen to trade A shares from HK.","listText":"<a href=\"https://laohu8.com/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>seeing english media stated something incorrect, just to share chinese version. It clearly stating only ban Mainland Chinese citizen to trade A shares from HK.","text":"$Futu Holdings Limited(FUTU)$seeing english media stated something incorrect, just to share chinese version. It clearly stating only ban Mainland Chinese citizen to trade A shares from HK.","images":[{"img":"https://static.tigerbbs.com/380e87351e461288e468f01865b9f494","width":"1080","height":"2340"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699139726","isVote":1,"tweetType":1,"viewCount":1337,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":818845624,"gmtCreate":1630398796768,"gmtModify":1631883690789,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>券商爆发，今晚美股有好戏看了","listText":"<a href=\"https://laohu8.com/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>券商爆发，今晚美股有好戏看了","text":"$Futu Holdings Limited(FUTU)$券商爆发，今晚美股有好戏看了","images":[{"img":"https://static.tigerbbs.com/4639169bb8acead2c8c809204114e57b","width":"1080","height":"2340"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/818845624","isVote":1,"tweetType":1,"viewCount":502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":606245554,"gmtCreate":1638888758239,"gmtModify":1638888758358,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SBLK\">$Star Bulk Carriers(SBLK)$</a>result of perseverance","listText":"<a href=\"https://laohu8.com/S/SBLK\">$Star Bulk Carriers(SBLK)$</a>result of perseverance","text":"$Star Bulk Carriers(SBLK)$result of perseverance","images":[{"img":"https://static.tigerbbs.com/883742c732dfc220779ac42190545e1d","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606245554","isVote":1,"tweetType":1,"viewCount":591,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":820706601,"gmtCreate":1633427138725,"gmtModify":1633427138933,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>second listing in HKSE!&nbsp;","listText":"<a href=\"https://laohu8.com/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>second listing in HKSE!&nbsp;","text":"$Futu Holdings Limited(FUTU)$second listing in HKSE!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820706601","isVote":1,"tweetType":1,"viewCount":110,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":812243156,"gmtCreate":1630591990275,"gmtModify":1631883690453,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>不错！","listText":"<a href=\"https://laohu8.com/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>不错！","text":"$Futu Holdings Limited(FUTU)$不错！","images":[{"img":"https://static.tigerbbs.com/37cdefb792cf5984324f3703066cfc1a","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812243156","isVote":1,"tweetType":1,"viewCount":359,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":639980436,"gmtCreate":1643120520742,"gmtModify":1643120520874,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZIM\">$ZIM Integrated Shipping Services Ltd.(ZIM)$</a>correction!","listText":"<a href=\"https://laohu8.com/S/ZIM\">$ZIM Integrated Shipping Services Ltd.(ZIM)$</a>correction!","text":"$ZIM Integrated Shipping Services Ltd.(ZIM)$correction!","images":[{"img":"https://static.tigerbbs.com/06d02ea906ad7803bfd7bc390f165069","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/639980436","isVote":1,"tweetType":1,"viewCount":801,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":630428453,"gmtCreate":1643026416922,"gmtModify":1643026417072,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZIM\">$ZIM Integrated Shipping Services Ltd.(ZIM)$</a>right decision? Hope so","listText":"<a href=\"https://laohu8.com/S/ZIM\">$ZIM Integrated Shipping Services Ltd.(ZIM)$</a>right decision? Hope so","text":"$ZIM Integrated Shipping Services Ltd.(ZIM)$right decision? Hope so","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630428453","isVote":1,"tweetType":1,"viewCount":724,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":630633740,"gmtCreate":1642808978890,"gmtModify":1642808979076,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good insight","listText":"Good insight","text":"Good insight","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630633740","repostId":"630808999","repostType":1,"repost":{"id":630808999,"gmtCreate":1642760372836,"gmtModify":1642760372836,"author":{"id":"3527667586584720","authorId":"3527667586584720","name":"小虎综合资讯","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"图解财报 | 奈飞遭遇“滑铁卢”的四大原因","htmlText":"周四，奈飞Q4财报公布后股价大跌，周五盘前继续跌势，不久前还因《鱿鱼游戏》火遍全球的科技巨头，为何坠入“至暗时刻”？","listText":"周四，奈飞Q4财报公布后股价大跌，周五盘前继续跌势，不久前还因《鱿鱼游戏》火遍全球的科技巨头，为何坠入“至暗时刻”？","text":"周四，奈飞Q4财报公布后股价大跌，周五盘前继续跌势，不久前还因《鱿鱼游戏》火遍全球的科技巨头，为何坠入“至暗时刻”？","images":[{"img":"https://static.tigerbbs.com/e43255443c4abf8889320585d25493d8","width":"750","height":"6580"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630808999","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":600,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":630924613,"gmtCreate":1642672953448,"gmtModify":1642672953585,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SBLK\">$Star Bulk Carriers(SBLK)$</a>correction yet come?&nbsp;","listText":"<a href=\"https://laohu8.com/S/SBLK\">$Star Bulk Carriers(SBLK)$</a>correction yet come?&nbsp;","text":"$Star Bulk Carriers(SBLK)$correction yet come?","images":[{"img":"https://static.tigerbbs.com/6305ca6e7aa7fc2d5b46d3f9f79cde21","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630924613","isVote":1,"tweetType":1,"viewCount":747,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":847456838,"gmtCreate":1636548911950,"gmtModify":1636548912173,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"All electric cars at crazy valuation","listText":"All electric cars at crazy valuation","text":"All electric cars at crazy valuation","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847456838","repostId":"1127288999","repostType":2,"repost":{"id":"1127288999","pubTimestamp":1636525634,"share":"https://www.laohu8.com/m/news/1127288999?lang=&edition=full","pubTime":"2021-11-10 14:27","market":"us","language":"en","title":"EV maker Rivian prices IPO above range to raise over $11.9 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1127288999","media":"Reuters","summary":"NEW YORK (Reuters) - Amazon-backed electric vehicle (EV) maker Rivian sold shares in its initial pub","content":"<p>NEW YORK (Reuters) - Amazon-backed electric vehicle (EV) maker Rivian sold shares in its initial public offering (IPO) at $78 per share, above its target range, to raise more than $11.93 billion, the company said on Tuesday.</p>\n<p>The flotation ranks among the top 10 IPOs of all time in the United States, according to data from Dealogic.</p>\n<p>Rivian priced an upsized IPO of 153 million shares at $78 per share, the company&nbsp;said. On Friday, Rivian had boosted its price range to $72 to $74 per share, up from an earlier range of $57 to $62.</p>\n<p>The mammoth IPO follows a highly successful investor roadshow last week, with Wall Street's biggest institutional investors betting on Rivian to be the next big player in a sector dominated by Tesla.</p>\n<p>The EV market is witnessing a surge in demand globally, as consumers are growing more environmentally conscious and betting on eco-friendly vehicles. Tesla produced a record number of cars in its latest quarter and is building factories all over the world.</p>\n<p>Founded in 2009, Rivian has been investing heavily to ramp up production. It is doubling down on production of its upscale all-electric R1T pickup truck, which was launched in September.</p>\n<p>The EV maker had about 55,400 R1T and R1S pre-orders in the United States and Canada as of Oct. 31, according to a recent regulatory filing.</p>\n<p>Rivian said it had started deliveries of the R1T and had recorded revenue for the three months ended Sept. 30. The net loss for that period, however, is estimated to increase due to higher production costs.</p>\n<p>Amazon, which recently disclosed it holds an approximately 20% stake in Rivian, has ordered 100,000 of Rivian's electric delivery vans as part of the e-commerce company's broader effort to cut its carbon footprint.</p>\n<p>Rivian will list its shares on the Nasdaq under the symbol \"RIVN\" on Wednesday.</p>\n<p>Morgan Stanley, Goldman Sachs and J.P. Morgan are the lead underwriters for the offering.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV maker Rivian prices IPO above range to raise over $11.9 billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV maker Rivian prices IPO above range to raise over $11.9 billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-10 14:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ev-maker-rivian-prices-ipo-002047558.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (Reuters) - Amazon-backed electric vehicle (EV) maker Rivian sold shares in its initial public offering (IPO) at $78 per share, above its target range, to raise more than $11.93 billion, the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ev-maker-rivian-prices-ipo-002047558.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc."},"source_url":"https://finance.yahoo.com/news/ev-maker-rivian-prices-ipo-002047558.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127288999","content_text":"NEW YORK (Reuters) - Amazon-backed electric vehicle (EV) maker Rivian sold shares in its initial public offering (IPO) at $78 per share, above its target range, to raise more than $11.93 billion, the company said on Tuesday.\nThe flotation ranks among the top 10 IPOs of all time in the United States, according to data from Dealogic.\nRivian priced an upsized IPO of 153 million shares at $78 per share, the company said. On Friday, Rivian had boosted its price range to $72 to $74 per share, up from an earlier range of $57 to $62.\nThe mammoth IPO follows a highly successful investor roadshow last week, with Wall Street's biggest institutional investors betting on Rivian to be the next big player in a sector dominated by Tesla.\nThe EV market is witnessing a surge in demand globally, as consumers are growing more environmentally conscious and betting on eco-friendly vehicles. Tesla produced a record number of cars in its latest quarter and is building factories all over the world.\nFounded in 2009, Rivian has been investing heavily to ramp up production. It is doubling down on production of its upscale all-electric R1T pickup truck, which was launched in September.\nThe EV maker had about 55,400 R1T and R1S pre-orders in the United States and Canada as of Oct. 31, according to a recent regulatory filing.\nRivian said it had started deliveries of the R1T and had recorded revenue for the three months ended Sept. 30. The net loss for that period, however, is estimated to increase due to higher production costs.\nAmazon, which recently disclosed it holds an approximately 20% stake in Rivian, has ordered 100,000 of Rivian's electric delivery vans as part of the e-commerce company's broader effort to cut its carbon footprint.\nRivian will list its shares on the Nasdaq under the symbol \"RIVN\" on Wednesday.\nMorgan Stanley, Goldman Sachs and J.P. Morgan are the lead underwriters for the offering.","news_type":1},"isVote":1,"tweetType":1,"viewCount":745,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859791663,"gmtCreate":1634731438214,"gmtModify":1634731492085,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"This NFT thing is really hard to comprehend, yet a billion dollar sector.","listText":"This NFT thing is really hard to comprehend, yet a billion dollar sector.","text":"This NFT thing is really hard to comprehend, yet a billion dollar sector.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859791663","repostId":"1157555199","repostType":2,"repost":{"id":"1157555199","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1634693372,"share":"https://www.laohu8.com/m/news/1157555199?lang=&edition=full","pubTime":"2021-10-20 09:29","market":"us","language":"en","title":"Coinbase Shares Jump On NBA Partnership: What Investors Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=1157555199","media":"Benzinga","summary":"A leading cryptocurrency platform announced a partnership with the National Basketball Association o","content":"<p>A leading cryptocurrency platform announced a partnership with the National Basketball Association on the day the league is set to kick off its 75th anniversary.</p>\n<p><img src=\"https://static.tigerbbs.com/71c079c80776647184cfcb0bff977ce5\" tg-width=\"720\" tg-height=\"378\" width=\"100%\" height=\"auto\"></p>\n<p><b>What Happened:</b>The National Basketball Association announced its first cryptocurrency sponsorship in a partnerhsip with&nbsp;<b>Coinbase Global Inc.</b></p>\n<p>“We’re excited to announce that as of today we are the official crypto platform of the NBA, WNBA, NBA2KLeague and USA Basketball,” Coinbasetweeted,&nbsp;tagging the respective leagues.</p>\n<p>“As part of the partnership, we will create interactive experiences to engage with the NBA and WNBA’s incredible community and athletes around the world,\" Coinbase Chief Marketing Officer&nbsp;<b>Kate Rouch</b>&nbsp;told&nbsp;CNBC&nbsp;in a statement.</p>\n<p><b>Why It’s Important:</b>The NBA&nbsp;has been earlier with&nbsp;cryptocurrency and&nbsp;NFTs. The league has&nbsp;the highly&nbsp;successful&nbsp;NBA Top Shot partnership with&nbsp;<b>Dapper Labs</b>. The Miami Heat have an arena naming deal with&nbsp;<b>FTX</b>&nbsp;and several teams have patch sponsorships with cryptocurrency companies.</p>\n<p>The NBA is projecting $10 billion in revenue for the 2021-22 season thanks to the return of fans. Sponsorship revenue was $1.4 billion last season.</p>\n<p>The NBA kicks off its 75th season with a doubleheader of marquee matchups. The Brooklyn Nets take on the Milwaukee Bucks at 7:30 p.m. ET and the Golden State Warriors take on the Los Angeles Lakers at 10 p.m. ET. Both games will air on TNT, a unit of&nbsp;<b>AT&amp;T Inc.</b></p>\n<p><b>COIN Price Action:</b>Coinbase&nbsp;shares were up 4% to $305.63 on Tuesday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coinbase Shares Jump On NBA Partnership: What Investors Should Know</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoinbase Shares Jump On NBA Partnership: What Investors Should Know\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-10-20 09:29</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>A leading cryptocurrency platform announced a partnership with the National Basketball Association on the day the league is set to kick off its 75th anniversary.</p>\n<p><img src=\"https://static.tigerbbs.com/71c079c80776647184cfcb0bff977ce5\" tg-width=\"720\" tg-height=\"378\" width=\"100%\" height=\"auto\"></p>\n<p><b>What Happened:</b>The National Basketball Association announced its first cryptocurrency sponsorship in a partnerhsip with&nbsp;<b>Coinbase Global Inc.</b></p>\n<p>“We’re excited to announce that as of today we are the official crypto platform of the NBA, WNBA, NBA2KLeague and USA Basketball,” Coinbasetweeted,&nbsp;tagging the respective leagues.</p>\n<p>“As part of the partnership, we will create interactive experiences to engage with the NBA and WNBA’s incredible community and athletes around the world,\" Coinbase Chief Marketing Officer&nbsp;<b>Kate Rouch</b>&nbsp;told&nbsp;CNBC&nbsp;in a statement.</p>\n<p><b>Why It’s Important:</b>The NBA&nbsp;has been earlier with&nbsp;cryptocurrency and&nbsp;NFTs. The league has&nbsp;the highly&nbsp;successful&nbsp;NBA Top Shot partnership with&nbsp;<b>Dapper Labs</b>. The Miami Heat have an arena naming deal with&nbsp;<b>FTX</b>&nbsp;and several teams have patch sponsorships with cryptocurrency companies.</p>\n<p>The NBA is projecting $10 billion in revenue for the 2021-22 season thanks to the return of fans. Sponsorship revenue was $1.4 billion last season.</p>\n<p>The NBA kicks off its 75th season with a doubleheader of marquee matchups. The Brooklyn Nets take on the Milwaukee Bucks at 7:30 p.m. ET and the Golden State Warriors take on the Los Angeles Lakers at 10 p.m. ET. Both games will air on TNT, a unit of&nbsp;<b>AT&amp;T Inc.</b></p>\n<p><b>COIN Price Action:</b>Coinbase&nbsp;shares were up 4% to $305.63 on Tuesday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157555199","content_text":"A leading cryptocurrency platform announced a partnership with the National Basketball Association on the day the league is set to kick off its 75th anniversary.\n\nWhat Happened:The National Basketball Association announced its first cryptocurrency sponsorship in a partnerhsip with Coinbase Global Inc.\n“We’re excited to announce that as of today we are the official crypto platform of the NBA, WNBA, NBA2KLeague and USA Basketball,” Coinbasetweeted, tagging the respective leagues.\n“As part of the partnership, we will create interactive experiences to engage with the NBA and WNBA’s incredible community and athletes around the world,\" Coinbase Chief Marketing Officer Kate Rouch told CNBC in a statement.\nWhy It’s Important:The NBA has been earlier with cryptocurrency and NFTs. The league has the highly successful NBA Top Shot partnership with Dapper Labs. The Miami Heat have an arena naming deal with FTX and several teams have patch sponsorships with cryptocurrency companies.\nThe NBA is projecting $10 billion in revenue for the 2021-22 season thanks to the return of fans. Sponsorship revenue was $1.4 billion last season.\nThe NBA kicks off its 75th season with a doubleheader of marquee matchups. The Brooklyn Nets take on the Milwaukee Bucks at 7:30 p.m. ET and the Golden State Warriors take on the Los Angeles Lakers at 10 p.m. ET. Both games will air on TNT, a unit of AT&T Inc.\nCOIN Price Action:Coinbase shares were up 4% to $305.63 on Tuesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":834490871,"gmtCreate":1629816941793,"gmtModify":1633682222099,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"好就没那么爽了！","listText":"好就没那么爽了！","text":"好就没那么爽了！","images":[{"img":"https://static.tigerbbs.com/34cf48712102c1579cb70b53d0113177","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/834490871","isVote":1,"tweetType":1,"viewCount":70,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":149208538,"gmtCreate":1625727041724,"gmtModify":1633937955301,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>吐血了","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>吐血了","text":"$Tiger Brokers(TIGR)$吐血了","images":[{"img":"https://static.tigerbbs.com/b3dfffcabec7bcfa52cddf5913330509","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/149208538","isVote":1,"tweetType":1,"viewCount":151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":128496090,"gmtCreate":1624526472310,"gmtModify":1634004866125,"author":{"id":"3582161512309317","authorId":"3582161512309317","name":"Ben_the_King","avatar":"https://static.tigerbbs.com/c6f71703a565dd7321dc4f3e075f63a0","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MF\">$Missfresh Limited(MF)$</a>尊敬的客户，接每日优鲜通知，因认购火爆，公司拟提前结束招股，预计6月25日正式上市。每日优鲜认购通道将于6月24日19:00（北京时间）关闭，如您意向认购或撤销，请在认购结束前操作，感谢您的理解和支持。如有问题请您联系客服400-603-7555。","listText":"<a href=\"https://laohu8.com/S/MF\">$Missfresh Limited(MF)$</a>尊敬的客户，接每日优鲜通知，因认购火爆，公司拟提前结束招股，预计6月25日正式上市。每日优鲜认购通道将于6月24日19:00（北京时间）关闭，如您意向认购或撤销，请在认购结束前操作，感谢您的理解和支持。如有问题请您联系客服400-603-7555。","text":"$Missfresh Limited(MF)$尊敬的客户，接每日优鲜通知，因认购火爆，公司拟提前结束招股，预计6月25日正式上市。每日优鲜认购通道将于6月24日19:00（北京时间）关闭，如您意向认购或撤销，请在认购结束前操作，感谢您的理解和支持。如有问题请您联系客服400-603-7555。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128496090","isVote":1,"tweetType":1,"viewCount":284,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}